The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
Total revenue during the third quarter was impacted by lower product sales in Africa, but the firm said it saw growth in the US, Latin America, and Asia Pacific.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The acquisition of immunohistochemistry services provider QualTek will augment Discovery's existing histopathology services, the company said.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.
The firms are also partnering to develop molecular diagnostic assays and for the supply of enzymes and oligonucleotides required for manufacturing.
Companies in the AMR space have met resistance from investors and clinicians as a result of conflicting hospital priorities and perceived technology shortcomings.